Table 4

Outcome measures of the clinical trials included in the systematic review

Outcome measureClinical trial (first author, year), reference
LIPCOFSchrell 201225
Schirmer testAll studies included in the systematic review8–25
Tear film break-up time (TF-BUT)Laibovitz 1993, Gunduz 1994, Sall 2000, Stevenson 2000, Sall 2006, Willen 2008, Guzey 2009, Kim 2009, Altiparmak 2010, Baiza-Duran 2010, Chen 2010, Rao 2010, Demiryay 2011, Rao 2011, Su 2011, Liew 2012, Schrell 20128–11 13–25
Vital dye staining of the ocular surfaceLaibovitz 1993, Gunduz 1994, Sall 2000, Stevenson 2000, Salib 2006, Sall 2006, Willen 2008, Guzey 2009, Kim 2009, Baiza-Duran 2010, Chen 2010, Rao 2010, Demiryay 2011, Rao 2011, Su 2011, Liew 2012, Schrell 20128–16 18–25
OSDI scoreSall 2000, Stevenson 2000, Salib 2006, Willen 2008, Guzey 2009, Kim 2009, Rao 2010 and 2011, Su 2011, Liew 2012, Schrell 201210–12 14–16 20 22–25
BCVASalib 200612
SignsLaibovitz 1993, Sall 2000, Stevenson 2000, Sall 2006, Baiza-Duran 2010, Chen 2010, Rao 20118 10 11 13 18 19 22
SymptomsLaibovitz 1993, Stevenson 2000, Sall 2000 and 2006, Kim 2009, Baiza-Duran 2010, Chen 20108 10 11 13 16 18 19
Total symptoms scoreGuzey 2009, Chen 2010 (total signs and symptoms score)15 19
Ocular Comfort Index (OCI)Liew 201224
Artificial tear useSall 2000, Stevenson 2000, Chen 2010, Rao 2011, Liew 201210 11 19 22 24
Conjunctival cytologyGuzey 2009, Kim 2009, Altiparmak 2010, Rao 2010, Demiryay 2011, Rao 201115–17 20–22
Dry eye progressionRao 2010 (evaluation based on International Task Force (ITF) guidelines), Rao 201120 22
QuestionnairesWillen 2008 (NEI-RQL-42)14
  • BCVA, best corrected visual acuity; LIPCOF, lid-parallel conjunctival folds; NEI-RQL-42, National Eye Institute Refractive Error Quality of Life instrument-42; OSDI, Ocular Surface Disease Index.